key: cord-1018846-n3gcg95y
authors: Brockow, Knut; Mathes, Sonja; Fischer, Jörg; Volc, Sebastian; Darsow, Ulf; Eberlein, Bernadette; Biedermann, Tilo
title: Experience with polyethylene glycol allergy‐guided risk management for COVID‐19 vaccine anaphylaxis
date: 2021-12-04
journal: Allergy
DOI: 10.1111/all.15183
sha: c59e604930ca26a72603c5a1319e5be46f86e8cf
doc_id: 1018846
cord_uid: n3gcg95y

BACKGROUND: Polyethylene glycol (PEG) may elicit anaphylaxis to COVID‐19 mRNA vaccines, and guidance for patients at risk is needed. METHODS: In retrospective patients with PEG allergy collected from 2006 till 2019, clinical, skin, and basophil activation test (BAT) characteristics discriminative for PEG allergy were analyzed and compared with the literature. In 421 prospective real‐life patients asking for allergy workup for COVID‐19 vaccine hypersensitivity in 2020/2021, risk assessment was performed and tolerance of the recommended vaccination approach was assessed. RESULTS: Ten patients with PEG allergy were found in the retrospective cohort. Patients reacted with immediate anaphylaxis (100%) not only to PEG‐based laxatives/bowel preparations or injections, but also to cold medication, antiseptics, analgetics, or antibiotics. Skin tests ± BAT with PEG ± elicitors were positive in 10/10. Provocation tests were positive in 7/9 patients. From the prospective cohort, 370/421 patients self‐reporting increased risk for vaccine allergy lacked criteria necessitating allergy workup and were recommended for routine vaccination. A total of 51/421 patients were tested, and three (6%) with PEG allergy were identified, whereas 48 patients remained negative in skin tests. Vaccination was recommended in all those patients. No hypersensitivity reactions were reported to vaccination including six PEG‐allergic patients tolerating COVID‐19 vaccination. CONCLUSIONS: Taking a detailed history excluded PEG allergy in most referred patients and enabled direct safe vaccination. Immediate urticaria/anaphylaxis to typical elicitors identified patients requiring PEG allergy workup. Skin tests ± BAT identified PEG allergy and helped to select the vaccine and the vaccination approach. Even PEG‐allergic patients can tolerate COVID‐19 vaccines.

and for chemical, biological, industrial, cosmetic, and recreational uses. 1 Anaphylaxis to PEG has been described. 2 and Johnson & Johnson (Janssen ® ) are vector-based vaccines containing polysorbate 80 (PS80) and trometamol. 2, 6 PEG is the only excipient in COVID-19 mRNA vaccines that clearly demonstrated to cause delayed-type and immediate-type allergic reactions, while the role of trometamol and PS80 as relevant allergens in DNA vaccines remain more questionable. [2] [3] [4] 7 Cases with anaphylaxis to mRNA vaccines for COVID-19 have been reported with an incidence of 4.7 cases/10 6 doses for the Comirnaty ® and 2.5/10 6 doses for Moderna vaccinations, about 2-4 times higher than that expected for other vaccinations. [8] [9] [10] [11] Such reports fueled public concern about the allergenic potential of PEG. 3, [12] [13] [14] [15] Several individuals report alleged hypersensitivity reactions to the first dose of COVID-19 vaccination.

Additionally, those with previous severe allergic reactions and anaphylaxis to a variety of elicitors including medications seek allergy testing before vaccination. 16, 17 Recommendations on how to manage patients at risk for PEG allergy have been published but have not been evaluated for their safety in real-life patients. [18] [19] [20] [21] [22] The objective of this study is to (a) identify clinical criteria in our patients with PEG allergy and compare these with criteria reported in the literature, (b) to apply these criteria to 421 prospective real-life patients who were asking for allergy workup for COVID -19 vaccine hypersensitivity, and (c) to report the outcome of the recommendations for patient management according to individual risk assessment.

Patients with immediate-type allergic reactions to PEG between 2006 and 2019 were retrospectively retrieved from the medical charts of two large allergy units in southern Germany (Table 1) .

Clinical data including history, skin prick (SPT), intradermal (IDT) and oral provocation test (OPT) results were extracted from the patient charts. Main clinical criteria were identified and compared with those published in the literature. 18 

a vaccine ingredient were assessed and managed prospectively as outlined in Figure 1 . Testing was carried out with vaccines, PEG, PS80, and trometamol, the latter only if relevant in the patient history (reaction to Moderna ® or other preparation containing trometamol). Patients without clinical criteria for PEG allergy (Table 3) were referred for direct vaccination without allergy tests, 1,6,18 as recommended by the algorithm of the German Federal Institute for Vaccines and Biomedicine (Paul Ehrlich Institute) and German allergy associations ( Figure S1 ), 21, 22 which mirrors other published recommendations. [18] [19] [20] Mastocytosis without criteria for vaccine excipient allergy was no indication for testing. 23 Unclear cases were handled by shared decision-making discussing the case between the allergy resident, allergy supervisors, and the department director.

Patients with suspicion for possible allergy to vaccine ingredient(s) were skin tested, and in patients with PEG allergy, the basophil activation test (BAT) was added as described and outlined in Table S1 and in Supplementary Methods.

Outcome of vaccinations with regard to hypersensitivity reactions was recorded by patient interview asking for events occurring within 1 hour and by telephone interview of those 51 patients in whom we performed allergy tests. We asked the patients without need of allergy workup to report to us, if such reactions occur.

Ten patients with confirmed IgE-mediated allergic reactions to PEG were identified in our two allergy units within the last 14 years (Table 1 ). This report includes the highest number of allergy-tested PEG-allergic patients in the literature. Nevertheless, our study spanning a 14-year period shows that PEG allergies are rare. In the medical history of PEG-allergic patients, reports of repeated reactions were frequent (40%), but not in the majority of patients. The common clinical manifestation was anaphylaxis according to the NIAID/ 

In total, 421 e-mails and telephone calls were received from patients or referring doctors self-reporting a history of COVID-19

vaccine hypersensitivity or alleged increased allergy risk for vaccination against COVID-19 ( Figure 1 (Table 3 ) and published recommendations ( Figure S1 )

were helpful to recommend direct vaccination without allergy test or additional precaution in 370 patients (88%). Hence, the vast majority of patients suspecting allergic reactions could be encouraged to proceed to vaccination without allergy tests by history alone ( Figure S1 , Table 3 ).

Other 51 patients (12%) were invited for allergy skin testing, when it was felt that an allergy to a vaccine ingredient could not be safely excluded by history alone. In three patients (6%), PEG allergy was diagnosed: In two patients, PEG allergy was newly diagnosed by us and in one patient externally 8 years ago. They were identified by their typical history and by positive SPT and IDT results (Table 4) .

BAT was positive in 3/3 PEG-allergic patients but not in controls ( Figure 2 , cording to the risk assessment (Figure 1 ).

In the retrospective cohort of 10 patients, one elderly patient died of cancer unrelated to allergy, three could not be contacted, two

were not yet vaccinated, and four patients tolerated vaccination against COVID-19: Two patients were vaccinated with Vaxzevria ® , but without our consultation also one patient tolerated two shots of Comirnaty ® with prophylactic antihistamine and one a Vaxzevria ® -Comirnaty ® cross-over vaccination.

In the 3/51 prospective skin test-identified PEG-allergic patients, 

PEG allergy has been widely discussed as cause of anaphylaxis to mRNA vaccines for COVID-19 protection. 4 To this end, we analyzed how many patients are eligible for vaccination just based on detailed history taking and found that 370/421 patients with concerns in regard to vaccine hypersensitivity could be referred to vaccination without further allergy workup ( Figure S1 , Table 3 ). In another 48/51 patients with negative skin tests, an allergy was largely excluded, which aided to select a less controlled vaccination approach. Of note, PEG hypersensitivity despite negative skin tests has been described and was seen also in one of our patients. 30 As we could not safely exclude non-allergic hypersensitivity (e.g., chronic or stress-associated urticaria and non-IgE-mediated hypersensitivity reactions) in 10 patients with immediate allergy-like and in 2 with anaphylaxis-like reactions despite negative skin test, we individually recommended prolonged observation, increased emergency preparedness and antihistamine premedication (for those with prominent urticaria), and/or fractionated vaccination ± inpatient setting for those with anaphylaxis-like reactions ( Figure 1 ). As none of our patients reported adverse reactions after taking the recommended shot, we conclude that the combined test regimen has a tolerable sensitivity. 25 In conclusion, in this largest allergy-tested series of patients with PEG allergy, we confirmed clinical criteria indicating PEG allergy (Table 3) , attested the practicability of existing recommendations ( Figure S1 ) 21, 35 , demonstrated the value of allergy tests for detecting PEG allergy, and safely vaccinated all patients, including those with PEG allergy with a DNA vaccine, by giving specific individual recommendations for the vaccination approach according to risk analysis and with shared decision-making.

This publication would not have been possible without the helpful cooperation of doctors Johann Wilhelm Weidringer, Philip

Kampmann, and Felix Jonas from the Munich Vaccination Center.

We are also grateful to Margitta Worm (Charité Berlin, Germany)

for suggesting and discussing skin test concentrations/allergy workup to all German Comprehensive Allergy Centers, and Vera

Mahler (Paul Ehrlich Institute, Abt. Allergologie) and other contributors from participating institutes/associations for creating the algorithm in Figure S1 and to our coworkers in our allergy department. Open access funding enabled and organized by Project DEAL.

The authors declare no conflicts of interest.

https://orcid.org/0000-0002-2775-3681

Sebastian Volc https://orcid.org/0000-0003-3543-4848

Immediate-type hypersensitivity to polyethylene glycols: a review

Polyethylene glycols (PEG) and related structures: overlooked allergens in the perioperative setting. A A Case Rep

Immediate hypersensitivity to polyethylene glycols and polysorbates: more common than we have recognized

Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioNTech mRNA COVID-19 vaccine

Polyethylene glycol-induced systemic allergic reactions (anaphylaxis)

Clinical manifestations and impact on daily life of allergy to polyethylene glycol (PEG) in ten patients

Delayedtype hypersensitivity dermatitis to ethylene oxide

Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US

Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine -United States

Vaccine-associated hypersensitivity

Vaccination and allergy: EAACI position paper, practical aspects

mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: current evidence and suggested approach

Anaphylaxis to the first COVID-19 vaccine: is polyethylene glycol (PEG) the culprit?

Practical recommendations for the allergological risk assessment of the COVID-19 vaccination -a harmonized statement of allergy centers in Germany

COVID-19 vaccineassociated anaphylaxis: a statement of the World Allergy Organization Anaphylaxis Committee

Successful SARS-CoV-2 vaccine allergy risk-management: the experience of a large Italian University Hospital

Acute allergic reactions to mRNA COVID-19 vaccines

Allergies and COVID-19 vaccines: an ENDA/EAACI position paper

The risk of allergic reaction to SARS-CoV-2 vaccines and recommended evaluation and management: a systematic review. meta-analysis: GRADE assessment, and international consensus approach

Optimizing investigation of suspected allergy to polyethylene glycols

Practical handling of allergic reactions to COVID-19 vaccines: a position paper from German and Austrian allergy societies AeDA, DGAKI, GPA and OGAI

Covid-19 vaccination and risk of anaphylaxis -recommendations for practical management

COVID-19 vaccination in mastocytosis: recommendations of the european competence network on mastocytosis (ECNM) and American initiative in mast cell diseases (AIM)

Second symposium on the definition and management of anaphylaxis: summary report-Second National Institute of Allergy and Infectious Disease/ Food Allergy and Anaphylaxis Network symposium

Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registrybased study of 414 cases

Allergic reactions to the first COVID-19 vaccine: a potential role of polyethylene glycol?

PEG that reaction: a case series of allergy to polyethylene glycol

Patients with suspected allergic reactions to COVID-19 vaccines can be safely revaccinated after diagnostic work-up

Safety evaluation of the second dose of messenger RNA COVID-19 vaccines in patients with immediate reactions to the first dose

Immediate allergic reactions by polyethylene glycol 4000: two cases

Safety of new mRNA vaccines against COVID-19 in severely allergic patients

Basophil reactivity to BNT162b2 is mediated by PEGylated lipid nanoparticles in PEG allergic patients

PEG skin testing for COVID-19 vaccine allergy

Double positivity to bee and wasp venom: improved diagnostic procedure by recombinant allergen-based IgE testing and basophil activation test including data about cross-reactive carbohydrate determinants

Was ist bei positiver Allergieanamnese vor einer Impfung gegen COVID-19 zu beachten?

Experience with polyethylene glycol allergy-guided risk management for COVID-19 vaccine anaphylaxis